🏛️ Verified NIH Record • Updated 2026-03-10
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy (NCT06174220)
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Hamilton Health Sciences Corporation
🩺 Plain-English Summary (8th-Grade Level)
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.
Who can join: Review the eligibility criteria below.
Location: University of Calgary — Calgary, Alberta
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- University of Calgary — Calgary, Alberta
- University of British Columbia — Vancouver, British Columbia
- Victoria Cardiac Arrhythmia Trials Inc. — Victoria, British Columbia
- NL Health Services — St. John's, Newfoundland and Labrador
- Nova Scotia Health — Halifax, Nova Scotia
- Hamilton General Hospital — Hamilton, Ontario
- Kingston General Hospital — Kingston, Ontario
- London Health Sciences Centre — London, Ontario
- Newmarket Electrophysiologist Research Group 'NERG' — Newmarket, Ontario
- University of Ottawa Heart Institute — Ottawa, Ontario
- Heart Health Institute Research Inc — Scarborough Village, Ontario
- Sunnybrook Health Sciences Centre — Toronto, Ontario
- St. Michael's Hospital — Toronto, Ontario
- Montreal Heart Institute — Montreal, Quebec
- McGill University Health Centre — Montreal, Quebec
- Hopital du Sacré-Coeur de Montréal — Montreal, Quebec
- University Institute of Cardiology and Pneumology of Quebec — Québec, Quebec
📞 Contact the Study Coordinator
Phone: (905) 521-2100
Email: jason.roberts@phri.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Arrhythmogenic Cardiomyopathy
- Gene Therapy for ACM Due to a PKP2 Pathogenic Variant — Stanford, California
- A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM — Redwood City, California
Explore by condition: All Arrhythmogenic Cardiomyopathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.